One of the reasons triple negative breast cancer is so lethal is because it does not respond to standard follow-up treatment, like tamoxifen or Arimedex, which is a highly successful therapy for hormone-negative cancer, although chemotherapy has been found to be effective for all hormone negative cancers.
Now, Komen for the Cure and the Triple Negative Breast Cancer Foundation have awarded $6.4 million to the University of Alabama at Birmingham to study the development of a drug to be used with chemotherapy to treating triple negative breast cancer.
Researchers will also study ways to predict the therapies that will be most effective against triple negative breast cancer.
More good news--evidence that this cancer has caught researchers' eye. Yea.
No comments:
Post a Comment